Trade Mark Journal No.2026/026 26 June 2026

UK00004402890 16 June 2026 (9,42,44)

MSK NEOQUAL

International priority date claimed: 18 December 2025 (United States of America) (99555012)

Class 9: Downloadable computer software and computer algorithms for analyzing next-generation sequencing data to identify and predict tumor-specific neoantigens for use in scientific research and medical research in the fields of oncology, immunology, and precision medicine.
Class 42: Non-downloadable computer software and computer algorithms for analyzing next-generation sequencing data to identify and predict tumor-specific neoantigens for use in scientific research and medical research in the fields of oncology, immunology, and precision medicine; providing scientific research and analysis services in the field of immunology, namely, proprietary methods for analyzing T cell receptor sequencing data for scientific and medical research and health treatment purposes; providing software for analyzing T cell receptor sequences and identifying T cell clonal lineages; bioinformatics services for identifying and tracking T cell populations in connection with monitoring immune response dynamics, endogenous and with therapeutic interventions; research in the biomedical sciences fields, including molecular biology, cell biology, genetics, and immunology; Medical initiative services, namely, research and development services pertaining to the development of cancer vaccines and treatment.
Class 44: Medical services; Healthcare services for treating cancer; Hospital services, namely, patient treatment and care; Pharmaceutical prescription formulation being compounding, and dispensing services; Providing medical services in the nature of patient consultations and medical information via telemedicine.

Memorial Sloan-Kettering Cancer Center

Representative: Barker Brettell LLP